Saturday 17 October 2026
Export CNTN’s income statement to Excel — free account
Canton Strategic Holdings, Inc.
CNTN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.9% and free cash flow fell 600.4%, each against the same quarter a year earlier.
1.70
0.17
−9.09%
Follow CNTN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 14.94 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (273.22) | |
P/B ratio |
— | — | — | 1.34 | |
Price to Tangible BV |
— | — | — | 0.00 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (25.94) | |
EV/FCF |
— | — | — | (25.94) | |
Quick Ratio |
4.93 | 3.65 | 36.39 | 14.18 | |
Current Ratio |
4.98 | 5.29 | 37.75 | 15.70 | |
Net Debt/EBITDA |
3.62 | 0.86 | 1.13 | 30.98 | |
Debt/Assets |
0.45% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.35 | 0.16 | 0.12 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(218.08) | (3,423.71) | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 180.36% | |
Intangible Assets out of Total Assets |
0.00 | 0.97 | 0.93 | 0.93 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 4.67% | |
Graham Net Nets |
— | — | — | (0.11) | |
Graham Number |
— | — | — | 2.98 | |
Earnings Yield |
— | — | — | 6.69% | |
Free Cash Flow Yield |
— | — | — | (3.63%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.30) | (0.33) | (0.04) | (0.01) | |
Capex per Share |
0.00 | (2.42) | (0.26) | (0.03) | |
Free Cash Flow per Share |
(0.30) | (2.75) | (0.30) | (0.04) | |
Cash per Share |
1.22 | 0.37 | 0.20 | 0.17 | |
Shareholders Equity per Share |
0.99 | 12.42 | 2.26 | 2.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.99 | 12.42 | 2.26 | 2.10 | |
Free Cash Flow |
(1.86) | (88.01) | (62.46) | (8.00) | |
Working Capital |
6.15 | 14.10 | 41.94 | 38.59 | |
Capital Expenditures |
— | (77.57) | (54.82) | (5.76) | |
Net Current Asset Value |
6.15 | (103.83) | (71.77) | (68.45) | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 3.85 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
0.72 | 0.81 | 0.62 | 0.84 | |
Average Assets |
6.48 | 261.43 | 293.16 | 283.55 | |
Average Common Equity |
4.59 | 199.62 | 234.49 | 227.64 |
Columns are period end dates